0001628280-24-024950.txt : 20240523
0001628280-24-024950.hdr.sgml : 20240523
20240523161810
ACCESSION NUMBER: 0001628280-24-024950
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240521
FILED AS OF DATE: 20240523
DATE AS OF CHANGE: 20240523
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Morales Mallory
CENTRAL INDEX KEY: 0001941795
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40675
FILM NUMBER: 24978524
MAIL ADDRESS:
STREET 1: C/O IMMUNEERING CORPORATION
STREET 2: 245 MAIN STREET, SECOND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Immuneering Corp
CENTRAL INDEX KEY: 0001790340
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 245 MAIN STREET, SECOND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-500-8080
MAIL ADDRESS:
STREET 1: 245 MAIN STREET, SECOND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
wk-form4_1716495475.xml
FORM 4
X0508
4
2024-05-21
0
0001790340
Immuneering Corp
IMRX
0001941795
Morales Mallory
C/O IMMUNEERING CORPORATION
245 MAIN STREET, SECOND FLOOR
CAMBRIDGE
MA
02142
0
1
0
0
Chief Accounting Officer
0
Stock Option
6.33
2024-05-21
4
D
0
10000
0
D
2032-08-11
Class A Common Stock
10000
0
D
Stock Option
3.01
2024-05-21
4
A
0
10000
0
A
2032-08-11
Class A Common Stock
10000
10000
D
Stock Option
9.66
2024-05-21
4
D
0
23850
0
D
2032-02-10
Class A Common Stock
23850
0
D
Stock Option
3.01
2024-05-21
4
A
0
23850
0
A
2032-02-10
Class A Common Stock
23850
23850
D
Stock Option
5.41
2024-05-21
4
D
0
5000
0
D
2032-06-30
Class A Common Stock
5000
0
D
Stock Option
3.01
2024-05-21
4
A
0
5000
0
A
2032-06-30
Class A Common Stock
5000
5000
D
Stock Option
9.55
2024-05-21
4
D
0
15000
0
D
2033-06-13
Class A Common Stock
15000
0
D
Stock Option
3.01
2024-05-21
4
A
0
15000
0
A
2033-06-13
Class A Common Stock
15000
15000
D
Stock Option
6.09
2024-05-21
4
D
0
60500
0
D
2034-02-08
Class A Common Stock
60500
0
D
Stock Option
3.01
2024-05-21
4
A
0
60500
0
A
2034-02-08
Class A Common Stock
60500
60500
D
Stock Option
4.25
2024-05-21
4
D
0
72000
0
D
2033-02-15
Class A Common Stock
72000
0
D
Stock Option
3.01
2024-05-21
4
A
0
72000
0
A
2033-02-15
Class A Common Stock
72000
72000
D
On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
This option is fully vested.
The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2022, and will be fully vested and exercisable on January 1, 2026.
The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on July 31, 2022, and will be fully vested and exercisable on June 30, 2026.
The option vests and becomes exercisable (subject to continued service to the Issuer through the applicable vesting date) in forty-eight (48) equal monthly installments following the vesting commencement date of July 1, 2023, and will be fully vested and exercisable on July 1, 2027.
The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2024, and will be fully vested and exercisable on January 1, 2028.
The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2023, and will be fully vested and exercisable on January 1, 2027.
/s/ Michael D. Bookman, Attorney-in-Fact for Mallory Morales
2024-05-23